DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Kyverna To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing Kyverna common stock pursuant and/or traceable to the O
Israeli Doctors from Save a Child’s Heart Deliver Christmas Miracles to Zambian Children
ROCKVILLE, Md., Dec. 24, 2024 /PRNewswire/ — In the spirit of the Christmas season, a team of Israeli doctors recently completed a humanitarian mission to Zambia, bringing hope and healing to 25 children suffering from critical heart conditions. The medical mission, a testament to the true mea
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DMC
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In DMC To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in DMC between May 3, 2024 and November 4, 2024 and would like to dis
Velo3D Announces Debt for Equity Exchange Transaction Significantly Delevers Balance Sheet Arrayed Notes Acquisition Corp to Become Majority Equity Holder of Velo3D
81.7% of the outstanding senior secured notes to be cancelled Velo3D Board of Directors Unanimously Approved the Transaction Velo3D to remain a public Company and continue to serve its customers FREMONT, Calif., Dec. 24, 2024 /PRNewswire/ — Velo3D, Inc. (OTCQX: VLDX) (“Velo3D” or t
Modern Wealth, an Independent and Fee-Only Investment Advisory Firm, Introduces Proprietary Advising Process for Entrepreneurs and Business Owners
BLUE BELL, Pa., Dec. 24, 2024 /PRNewswire/ — Modern Wealth, under the visionary leadership of its Founder and CEO Alan Rhode, CFP®, CPWA®, CVGA®, CEPA®, RLP®, is redefining how business owners and entrepreneurs approach business value growth and exit planning. Central to its Dynamic Plan
Virtusa Positioned as a Leader in NelsonHall’s 2024 Quality Engineering NEAT Report for Multiple Market Segments
SOUTHBOROUGH, Mass., Dec. 24, 2024 /PRNewswire/ — Virtusa Corporation, a global leader in digital business strategy, digital engineering, and IT services, has been positioned as a ‘Leader’ in the newly released NelsonHall 2024 NEAT (NelsonHall Vendor Evaluation and Assessment Tool)
AGM Group Holdings Inc. Highlights Strategic Growth and Future Initiatives in AI and Cryptocurrency
BEIJING, Dec. 24, 2024 /PRNewswire/ — AGM Group Holdings Inc. (“AGM Holdings” or the “Company”) (NASDAQ: AGMH), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, released a statement of its CE
Spectral Capital Announces Transformation into a Deep Quantum Technology Platform
SEATTLE, Dec. 24, 2024 /PRNewswire/ — Spectral Capital Corporation (OTCQB: FCCN), a pioneer in quantum innovation, proudly announces its transformation into a Deep Quantum Technology Platform. This strategic evolution positions Spectral at the forefront of the quantum era, uniting proprietary
Bio-Thera Solutions Partners with Tabuk Pharmaceuticals to Commercialize BAT2206, a Stelara® (Ustekinumab) Biosimilar in Saudi Arabia
GUANGZHOU, China, Dec. 24, 2024 /PRNewswire/ — Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has partnered with Tabuk Pharmaceutical Manufacturing Co
Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS
NANTONG and SUZHOU, China, Dec. 24, 2024 /PRNewswire/ — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I clinical trial of RAG-17, an innovative siRNA
